ClinicalTrials.gg
Active, not recruitingNCT06742190EmpassionUpdated Sep 22, 2026

A Study to Assess the Efficacy and Safety of Empasiprubart Versus IVIg in Adults With Multifocal Motor Neuropathy

A Phase 3 interventional study of Empasiprubart and IVIG (Intravenous Immunoglobulin) in Multifocal Motor Neuropathy (MMN) and MMN, sponsored by argenx. Active, not recruiting at 109 sites in 26 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-09-22.

Sponsored by argenx · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
154
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Study summary

The main purpose of this study is to compare empasiprubart and IVIg in adult patients with MMN. The study consists of a double-blinded part A (empasiprubart, IVIg) and an open-label part B (empasiprubart). The maximum study duration for participants is up to 49 months.

More information can be found here: https://clinicaltrials.argenx.com/empassion

02

Conditions studied

  • Multifocal Motor Neuropathy (MMN)
  • MMN
03

In context

Lead sponsor

argenx is the lead sponsor of 87 studies on the registry; 28 are open to participants now.

Of its 22 completed or terminated interventional studies of FDA-regulated products, 16 (73%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Is at least 18 years of age and the local legal age of consent for clinical studies
  • Has a confirmed diagnosis of definite or probable MMN at screening according to the EFNS/PNS 2010 guidelines
  • Has responded to IVIg in the past 5 years.
  • Is receiving IVIg at a treatment interval of once every 2, 3, 4, or 5 weeks, and a dose of 0.4 to 2.0 g/kg body weight per cycle
  • Is receiving a maintenance regimen (no change in frequency, and no change in dose >10%) of IVIg for at least 8 weeks before screening (or at least 10 weeks for participants receiving IVIg once every 5 weeks)
  • Minimum converted weekly IVIg dose of ≥0.125 g/kg
  • Has documented immunization against encapsulated bacterial pathogens (N meningitidis and S pneumoniae) within 5 years of screening or is willing to receive immunization at least 14 days before first study drug administration

Exclusion criteria

Exclusion Criteria:

  • Besides the indication under study, known disease (eg, SLE) or any other medical condition that would confound the study results or put the participant at undue risk
  • Clinical signs or symptoms suggestive of neuropathies other than MMN, such as motor neuron disease (eg, bulbar signs, brisk reflexes) or other inflammatory neuropathies (eg, sensory neuropathy)
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
154 participants (actual)

Study arms

  • Experimental
    Part A - empasiprubart + IVIg-placebo

    During the double blinded - double dummy part A, participants receive empasiprubart and a placebo resembling the IVIg treatment in this arm

    Biological: Empasiprubart · Other: IVIg-placebo

  • Active comparator
    Part A - IVIg + empasiprubart-placebo

    During the double blinded - double dummy part A, participants receive IVIg and a placebo resembling the empasiprubart treatment in this arm

    Biological: IVIG (Intravenous Immunoglobulin) · Other: Empasiprubart-placebo

  • Experimental
    Part B - empasiprubart

    After completion of part A, participants can proceed to part B where they receive empasiprubart (no IVIg)

    Biological: Empasiprubart

Interventions

  • BiologicalEmpasiprubart

    Intravenous infusion of empasiprubart

  • Intravenous infusion of IVIg

  • OtherEmpasiprubart-placebo

    A placebo resembling the empasiprubart treatment

  • OtherIVIg-placebo

    A placebo resembling the IVIg treatment

06

What researchers measure

Primary outcomes

  1. Change from baseline in grip strength (4-week average) in the most affected hand at week 24

    Time frame: Up to 24 weeks

Secondary outcomes

  1. Change from baseline in MMN-RODS centile score at week 24

    The 25-Item Rasch-Built Overall Disability Scale for MMN (MMN-RODS) is a questionnaire about the relationship between daily activities and the participants' health

    Time frame: Up to 24 weeks

  2. Change from baseline in mMRC-14 sum score

    The modified Medical Research Council (mMRC)-14 is a questionnaire where each muscle group is scored from 0 (paralysis) to 5 (normal strength). A higher value indicates better muscle strength. The total score is based on the sum of both the left and right side of the body.

    Time frame: Up to 24 weeks (Part A), Up to 120 weeks (Part B)

  3. PGI-C actual value

    The Patient Global Impression of Change (PGI-C) is a 7-point scale depicting a participant's rating of overall improvement. The lower the score, the better the improvement.

    Time frame: Up to 24 weeks (Part A), Up to 120 weeks (Part B)

  4. Change from baseline in CAP-PRI total score

    The Chronic Acquired Polyneuropathy Patient-Reported Index (CAP-PRI) includes the assessment of 15 items. Items will be scored 0 (not at all), 1 (a little bit), or 2 (a lot), yielding a total score that ranges from 0 to 30.

    Time frame: Up to 24 weeks (Part A), Up to 120 weeks (Part B)

  5. Percentage change from baseline in time to complete the 9-HPT with the dominant hand

    The 9-Hole Peg Test (9-HPT) is a quantitative measure of upper extremity (arm and hand) function. Both the dominant and nondominant hands will be tested twice (2 consecutive trials of the dominant hand, followed immediately by 2 consecutive trials of the nondominant hand).

    Time frame: Up to 24 weeks (Part A), Up to 120 weeks (Part B)

  6. Incidence of AEs, AESIs and SAEs

    Time frame: Up to 24 weeks (Part A), Up to 120 weeks (Part B)

  7. Serum concentrations over time of empasiprubart

    Time frame: Up to 24 weeks (Part A), Up to 120 weeks (Part B)

  8. Percent changes from baseline in free C2 and total C2 over time

    Time frame: Up to 24 weeks (Part A), Up to 120 weeks (Part B)

  9. Incidence of anti-drug antibodies (ADA) against empasiprubart in serum

    Time frame: Up to 24 weeks (Part A), Up to 120 weeks (Part B)

  10. Incidence of NAb against empasiprubart in serum

    Time frame: Up to 24 weeks (Part A), Up to 120 weeks (Part B)

  11. Change from baseline in grip strength (3-day moving average) of the least affected hand over time

    Time frame: Up to 24 weeks

  12. AUC of change from baseline in grip strength (3-day moving average) for the most and least affected hands

    Time frame: Up to 24 weeks

  13. Percentage change from baseline in time to complete the 9-HPT with the nondominant hand over time

    The 9-Hole Peg Test (9-HPT) is a quantitative measure of upper extremity (arm and hand) function. Both the dominant and nondominant hands will be tested twice (2 consecutive trials of the dominant hand, followed immediately by 2 consecutive trials of the nondominant hand).

    Time frame: Up to 24 weeks (Part A), Up to 120 weeks (Part B)

  14. Change from baseline in sum scores for mMRC-10 and mMRC-14 restricted to the 2 most affected muscle groups over time

    The modified Medical Research Council (mMRC) is a questionnaire where each muscle group is scored from 0 (paralysis) to 5 (normal strength). A higher value indicates better muscle strength. The total score is based on the sum of both the left and right side of the body.

    Time frame: Up to 24 weeks (Part A), Up to 120 weeks (Part B)

  15. Proportion of participants and shift from baseline over time by level of severity on PGI-S

    Patient Global Impression of Severity (PGIS) is a 7-point scale depicting a participant's rating of overall illness severity. Higher scores mean a higher severity.

    Time frame: Up to 24 weeks

  16. Change from baseline in Rasch-Transformed Fatigue Severity Scale (RT-FSS) score over time

    Time frame: Up to 24 weeks (Part A), Up to 120 weeks (Part B)

  17. Change from baseline in physical component and mental component scores of 12-Item Short Form Survey (SF-12) over time

    Time frame: Up to 24 weeks (Part A), Up to 120 weeks (Part B)

  18. Proportion of participants and shift from baseline by each dimension of the EQ-5D-5L scale

    Time frame: Up to 24 weeks (Part A), Up to 120 weeks (Part B)

  19. Changes from baseline in MMN-RODS centile score

    The 25-Item Rasch-Built Overall Disability Scale for MMN (MMN-RODS) is a questionnaire about the relationship between daily activities and the participants' health

    Time frame: Up to 120 weeks (part B)

  20. Changes from baseline in grip strength (3-day moving average; both hands)

    Time frame: Up to 120 weeks (part B)

  21. Actual values of PGI-S over time

    Patient Global Impression of Severity (PGIS) is a 7-point scale depicting a participant's rating of overall illness severity. Higher scores mean a higher severity.

    Time frame: Up to 120 weeks (part B)

  22. Change from baseline in grip strength (3-day moving average) in the most affected hand at week 24

    Time frame: Up to 24 weeks

07

Study locations

109 sites

Showing the first 100 of 109 sites across 26 countries. Choose a country and city above to see the rest.

08

References and documents

Related links

Individual participant data

Plan to share: No

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Dec 2024 (actual). Primary completion is estimated for Sep 2026, 21 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 16, 2024
First posted
Dec 19, 2024
StartActual
Dec 18, 2024
Primary completionEst.
Sep 2026
CompletionEst.
Dec 2029
Last update
Sep 22, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 22, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06742190
Lead sponsor
argenx
Responsible party
Sponsor
First posted
Dec 19, 2024
Start date
Dec 18, 2024
Primary completion
Sep 2026 (estimated)
Completion
Dec 2029 (estimated)
Last update
Sep 22, 2026

Oversight

FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Apr 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Empasiprubart

Start the discussion